Pfizer (NYSE:PFE) and Astellas reported Phase 3 data showing PADCEV plus Keytruda delivered significant clinical benefits in muscle-invasive bladder cancer. The combination was associated with ...
Pfizer (NYSE: PFE) is one of the world's largest pharmaceutical companies. It has a long history of innovation and success. Add in a lofty 6.6% dividend yield, and dividend investors are likely to ...
Pfizer (NYSE:PFE) reported positive topline results from its pivotal BREAKWATER trial. The study evaluated a BRAFTOVI based combination in previously untreated metastatic colorectal cancer with a BRAF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results